Nihan Burul Bozkurt, PhD Appointed Deputy Secretary General of AIFD
19.03.2026
Nihan Burul Bozkurt, PhD, who has successfully served as Health Policies Director at AIFD since 2021, has been appointed as AIFD’s Deputy Secretary General
AIFD, which works to accelerate access to innovative medicines and treatments in Türkiye and to strengthen the country’s global competitiveness in pharmaceutical research and development, continues to reinforce its organizational structure. Nihan Burul Bozkurt, PhD, who has served as Health Policies Director at AIFD since 2021, has been appointed as the association’s Deputy Secretary General. In her new role, Bozkurt will continue her leadership in the Health Science Policies Strategic Management Committee while also overseeing AIFD’s relations with the international organizations of which it is a member: the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Nihan Burul Bozkurt, PhD will also serve as co-spokesperson of the association together with the Secretary General of AIFD. After graduating from the Faculty of Pharmacy at Hacettepe University, Nihan Burul Bozkurt, PhD obtained both her master’s and doctoral degrees in pharmacology from the same university. She began her professional career in 2000 as a research assistant at Hacettepe University’s Faculty of Pharmacy and conducted research on Alzheimer’s disease in several countries as a visiting researcher. Between 2014 and 2016, Bozkurt served as Clinical Director at the Novagenix Bio-Analytical Drug R&D Center. From 2016 to 2021, she worked at the Turkish Medicines and Medical Devices Agency as Head of the Department of Clinical Trials. Joining AIFD in 2021 as Health Policies Director and leading the work of the Health Science Policies Strategic Management Committee, Bozkurt demonstrated strong leadership in significantly accelerating Türkiye’s alignment with global best regulatory practices and played a key role in developing and advancing AIFD’s clinical research strategy.